Table 3.
Plasma anticoagulant activity following repetitive oral unfractionated heparin administration
| Route | Dose (mg kg−1) | Dose intervals (h) | No. of dosages | APTT (s) | Anti-Xa activity (μg ml−1) | Anti-Iia activity (μg ml−1) |
|---|---|---|---|---|---|---|
| Oral | 7.5 | Single | 1 | 18.67±0.8 | — | — |
| Oral | 7.5 | 12 | 3 | 25.07±0.9a,b,c,d | 1.96±0.0 | — |
| Oral | 7.5 | 24 | 3 | 22.91±0.8a,b,c,d | 0.84±0.2 | — |
| Oral | 7.5 | 48 | 3 | 17.78±0.6 | 0.95±0.0 | — |
| Oral | 7.5 | 72 | 3 | 17.18±0.5a | 2.81±0.2 | — |
| Oral | 1 | 48 | 3 | 21.43±1.0 | — | — |
| Oral | 1 | 48 | 15 | 16.88±0.6a,e | 0.44±0.2 | 0.05±0.05 |
| s.c. | 1 | 48 | 15 | 17.26±0.5a,e | 4.35±0.6 | 0.00±0.00 |
| Oral | Saline | 20.04±0.7 | 3.81±0.7 | 0.00±0.00 |
Abbreviations: ANOVA, analysis of variance; APTT, activated partial thromboplastin time; s.c., subcutaneous.
Significantly different than acontrol, bsingle, c48 h, d72 h, e3 × 1 mg kg−1 48 h−1. One-way ANOVA, Tukey's multiple comparison test. —, not determined